Hepatitis B virus (HBV) is one of the main pathogens responsible for hepatitis and hepatocellular carcinoma. Human plasma-derived Hepatitis B immune globulin (HBIG) is being used for prophylactic and liver transplantation currently. However, it may be necessary to replace a HBIG with a recombinant one because of limited availability of human plasma with high anti-HBs antibody titer and possible contamination of human pathogens. To meet these requirements, a Chinese hamster ovary (CHO) cell line, HB-C7A, was established which produces a fully human IgG1 that binds HBV. The HB-C7A recognizes the conformational “a” determinant of HBsAg and binds HBV particle more efficiently than the Hepabig (a plasma-derived HBIG from Green Cross Corp., Yongin, Korea). The virus neutralizing efficacy of this antibody was proved using HBV-naïve chimpanzees. The HB-C7A exhibits ∼3500 units/mg of antibody and its affinity (Ka) is estimated ∼7 fold higher than that of Hepabig. The HB-C7A binds to HBVinfected human liver tissue but does not bind to normal human tissues. Currently it is in clinical phase I. In addition the possibility of chronic hepatitis B treatment by this antibody was investigated. This HB-C7A has several advantages compared to the Hepabig such as activity, safety and availability.
저자
Se-Ho Kim [ Research Director, Research Center, Green Cross Corp., Korea ]
한국생물공학회 [The Korean Society for Biotechnology and Bioengineering]
설립연도
1984
분야
공학>생물공학
소개
이 법인은 생물 공학의 발전과 보급에 이바지하고, 회원 상호 간의 연구 협력과 친목을 도모함을 목적으로 한다
1. 생물공학 분야의 발전을 위한 연구 협력
2. 생물공학의 실용화를 촉진시키기 위한 산학 협동
3. 학술연구 발표회, 강연회, 연수회 등 학술활동의 개최
4. 국,영문 학술지,소식지,학술회의 Proceedings 및 학술도서의 발간
5. 생물공학 발전을 위한 정책 건의
6. 기타 국제 교류 등 본 학회의 목적 달성을 위한 제반 활동